A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy

Article ID	Journal	Published Year	Pages	File Type
8454607	Lung Cancer	2016	8 Pages	PDF

Abstract

Second-line ramucirumab-docetaxel improved PFS similar to that seen in the REVEL trial with a manageable safety profile in Japanese patients with NSCLC.

Keywords

EGFR MedDRA ECoG FAS DCR ORR Ramucirumab TKI Randomized phase II trial NCI-CTCAE PFs ILD MRI progression-free survival overall survival Interstitial lung disease stable disease progressive disease full analysis set Magnetic resonance imaging computed tomography RECIST Docetaxel Medical Dictionary for Regulatory Activities Non-small-cell lung cancer NSCLC Non-small cell lung cancer eastern cooperative oncology group adverse event confidence interval Vascular endothelial growth factor Vascular Endothelial Growth Factor (VEGF)Response Evaluation Criteria in Solid Tumors Tyrosine kinase inhibitor objective response rate Disease control rate hazard ratio Performance status Partial response complete response Japan Epidermal growth factor receptor

Related Topics

Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research

Preview

A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy

Authors

Kiyotaka MD, Yukio MD PhD, Kazuo MD PhD, Kazuhiko MD PhD, Toshiaki MD, Nobuyuki MD PhD, Makoto MD PhD, Yuichiro MD PhD, Toshiko PhD, Takashi MPH, Sotaro MD PhD, Pablo MD, David PhD, Tomohide MD, Kazuhiko MD PhD,